×
Answer Capsule: 26 U.S. Code Section 174 governs the capitalization and amortization of research and experimental expenditures. For tax years beginning in 2022 through 2024, the TCJA required five-year amortization for domestic research and fifteen-year amortization for foreign research. For tax years beginning after December 31, 2024, Section 174A generally permits immediate deduction of domestic research costs, while foreign research remains subject to fifteen-year amortization, and states such as California follow their own rules.

26 U.S. Code Section 174: Capitalization, Section 174A, Section 41 Interplay, and State Conformity

26 U.S. Code Section 174 currently governs the capitalization and amortization of foreign Research and Experimental (R&E) expenditures over a fifteen-year period. For tax years beginning in 2022 through 2024, the TCJA version generally required five-year amortization for domestic activities and fifteen-year amortization for foreign activities. For tax years beginning after December 31, 2024, Section 174A generally permits immediate deduction of domestic R&E expenditures, subject to available elections and transition rules.

The transition from a historical posture of immediate expensing to a framework of mandatory capitalization represents one of the most profound structural shifts in United States corporate taxation in the modern era. Enacted through the Tax Cuts and Jobs Act (TCJA) of 2017, and taking effect for tax years beginning after December 31, 2021, the amended Section 174 redefined the financial mechanics of corporate innovation. By requiring taxpayers to capitalize Specified Research or Experimental (SRE) expenditures, the federal government transformed a long-standing innovation incentive into a broad revenue-raising mechanism. This statutory overhaul has triggered complex downstream effects, significantly impacting the calculation of the Section 41 Credit for Increasing Research Activities, altering ASC 740 tax provision reporting, and introducing immense compliance friction due to widespread state-level nonconformity. Jurisdictions such as the State of California, guided by the Franchise Tax Board (FTB), have explicitly decoupled from these federal mandates, preserving the immediate expensing rules and creating a deeply bifurcated compliance landscape. Furthermore, recent legislative actions, notably the 2025 One Big Beautiful Bill Act (OBBBA), have introduced modern complexities by restoring domestic expensing under a new Section 174A, while rigorously enforcing the capitalization of foreign research. This study provides a granular, expert-level examination of 26 U.S. Code Section 174, tracing its statutory evolution, dissecting federal explanatory memoranda and state executive branch interpretations, synthesizing landmark judicial rulings, and providing practical guidance for navigating the friction between federal amortization and state R&D tax credit frameworks.

Statutory Framework and the Historical Evolution of Section 174

The Genesis of the Innovation Incentive (1954–2021)

To fully comprehend the capitalization mandate, it is essential to trace the statutory origins of Section 174. Enacted as part of the Internal Revenue Code of 1954, the original provision addressed uncertainty over the tax treatment of research and development costs. Before its enactment, treatment depended on the nature of the expenditures and the taxpayer’s circumstances; some costs required capitalization. Recovery of capitalized costs could depend on an asset’s useful life or the availability of an abandonment loss under the applicable loss provisions.

The 1954 legislation introduced a statutory framework specifically designed to stimulate economic growth, technological advancement, and American competitiveness. By allowing taxpayers the option to either immediately deduct R&E expenditures as ordinary and necessary business expenses (akin to Section 162) or to elect to defer and amortize them over a period of not less than 60 months, the federal government effectively subsidized the inherent risk of innovation. For decades, this framework allowed companies, particularly pre-revenue startups and capital-intensive manufacturers, to optimize their cash flows by offsetting taxable income with the immediate deduction of their developmental costs.

The TCJA Capitalization Mandate (2022–2024)

The landscape of American innovation taxation was radically altered by the passage of the Tax Cuts and Jobs Act of 2017. In an effort to broaden the tax base and offset the significant revenue losses associated with lowering the top corporate tax rate from 35% to 21%, Congress amended Section 174. Effective for taxable years beginning after December 31, 2021, the TCJA stripped taxpayers of the option to immediately expense R&E expenditures. The amended statute required that all domestic SRE expenditures be capitalized and amortized ratably over a five-year period (60 months), beginning at the midpoint of the taxable year in which the expenses were paid or incurred.

Simultaneously, the legislation introduced different recovery periods based on the location of research. Expenditures attributable to foreign research activities were subjected to a 15-year (180-month) amortization period. This longer recovery period delayed deductions for foreign research relative to domestic research. Furthermore, the TCJA introduced a statutory mandate that all software development costs be automatically treated as SRE expenditures, sweeping vast swaths of standard technology sector operational costs into the capitalization net, regardless of whether the software was intended for internal use or commercial sale.

The 2025 Legislative Corrections: The OBBBA and Section 174A

The TCJA capitalization rules created cash flow concerns for research-intensive businesses. Congress subsequently enacted the One Big Beautiful Bill Act (OBBBA) in 2025. The OBBBA partially restored the original intent of the 1954 legislation by enacting a new provision, Section 174A, which permits the immediate expensing of domestic R&E expenditures, including domestic software development costs.

However, the legislation retained the TCJA’s 15-year mandatory capitalization requirement for foreign research expenditures. This preserves different treatment for domestic and foreign research. The transition to deductibility under Section 174A is generally treated as a taxpayer-initiated change in accounting method applied on a cut-off basis. For domestic costs capitalized in tax years beginning in 2022 through 2024, eligible transition elections allow recovery of the remaining unamortized amount in the first tax year beginning after 2024 or ratably over that year and the following year; otherwise, the existing amortization generally continues. These transition elections should not be confused with the separate Section 481(a) adjustments that may apply to corrections of an accounting method. The historical TCJA rules remain relevant for audits, unrecovered basis tracking, and state tax compliance in jurisdictions that have not adopted the federal amendments.

Defining Specified Research or Experimental (SRE) Expenditures

The reclassification of costs into the “Specified Research or Experimental” (SRE) category under the TCJA demanded a rigorous reevaluation of corporate cost accounting. The definition of an SRE expenditure encompasses much more than just the direct wages of laboratory scientists or engineers; it captures a broad, comprehensive spectrum of both direct and indirect costs associated with the innovation lifecycle.

Treasury Regulation § 1.174-2 Parameters and the Uncertainty Test

The foundational definition of qualifying expenditures is found in Treasury Regulation § 1.174-2(a)(1), which defines R&E expenditures as costs incurred in connection with a taxpayer’s trade or business that represent research and development costs in the “experimental or laboratory sense”. The regulation explicitly states that expenditures meet this threshold if they are for activities intended to discover information that would eliminate uncertainty concerning the development or improvement of a product.

Uncertainty is legally defined as existing if the information available to the taxpayer does not establish the capability, the method, or the appropriate design for developing or improving the product. Crucially, the ultimate success, failure, commercial viability, sale, or use of the product is entirely irrelevant to its eligibility under Section 174. The definition focuses on activities intended to eliminate uncertainty, rather than merely on whether they succeed.

The regulation defines a “product” in the broadest possible terms, encompassing any pilot model, process, formula, invention, technique, patent, or similar property, whether used internally by the taxpayer or held for sale, lease, or license. A “pilot model” is specifically defined as any representation or model of a product produced to evaluate and resolve uncertainty during development.

Furthermore, Treas. Reg. § 1.174-2(a)(5) introduces the vital “shrink-back” rule. This rule dictates that if the overall product does not meet the uncertainty test, the taxpayer must systematically evaluate the expenditures at the level of the component or subcomponent. The presence of uncertainty concerning the development of a specific subcomponent does not automatically qualify the entire overarching system, requiring meticulous cost segregation.

Explicit Inclusions in the SRE Cost Pool

Under IRS Notice 2023-63, as clarified and modified by Notice 2024-12, which provides interim guidance for the TCJA-era Section 174 rules, SRE expenditures are defined to include all costs incident to SRE activities. The inclusion net is cast incredibly wide, capturing the following cost categories:

Explicit Inclusions in the Section 174 SRE Cost Pool
Expenditure Category Scope of Inclusion under Section 174 SRE Definition
Labor Costs Includes basic compensation, stock-based compensation, overtime pay, vacation pay, holiday pay, sick leave, payroll taxes, pension costs, and employee benefits for full-time, part-time, and contract employees who perform, supervise, or directly support SRE activities. Severance compensation is explicitly excluded.
Materials and Supplies Costs of tangible consumables utilized in the direct conduct of experimental activities or the construction of pilot models.
Cost Recovery Allowances Depreciation, amortization, and depletion allowances on capital assets (e.g., testing equipment, servers, laboratory facilities) utilized in the performance of SRE activities.
Operations and Management Overhead costs including rent, utilities, insurance, property taxes, repairs and maintenance, and security costs. These must be allocated based on a reasonable cause-and-effect relationship, such as the square footage of the research facility relative to the total corporate footprint.
Travel and Patent Costs Travel costs directly linked to SRE activities and the costs of obtaining a patent (including attorneys’ fees expended in making and perfecting a patent application).

Statutory and Regulatory Exclusions

Conversely, Treasury Regulations and IRS Notices explicitly exclude specific operational costs from Section 174 treatment, requiring them to be treated under standard Section 162 operating expense rules or other applicable capitalization statutes. General and administrative (G&A) service department costs that only indirectly support research—such as human resources personnel hiring scientists, or accounting departments processing R&D payroll—are excluded. Additionally, interest on debt financing utilized to fund SRE activities, website hosting costs, routine quality control testing, efficiency surveys, management studies, consumer market surveys, and advertising or promotional expenditures do not qualify as SREs.

The Software Development Mandate

One of the most disruptive and universally applied elements of the TCJA amendments was the absolute inclusion of software development costs within Section 174(c)(3). Prior to 2022, software development enjoyed a protective safe harbor under Rev. Proc. 2000-50, which allowed for immediate expensing regardless of strict adherence to the Section 174 uncertainty tests. For tax years beginning in 2022 through 2024, the TCJA required software development costs to be capitalized and amortized; the corresponding provision of Rev. Proc. 2000-50 became obsolete for costs in tax years beginning after 2021. Domestic software development expenditures in tax years beginning after 2024 generally fall under Section 174A.

For the TCJA capitalization framework, Notice 2023-63 provides a comprehensive definition of software development activities, stipulating that the planning, designing, building of models, writing of source code, conversion of source code to machine-readable code, and the testing of the software must all be capitalized. Furthermore, “upgrades and enhancements” that result in additional functionality or materially increase the speed or efficiency of the software are treated as SREs.

However, the IRS established specific boundaries to prevent routine IT operations from being swept into the capitalization requirement. Activities excluded from software development under the notice may still require capitalization under other applicable tax rules. These exclusions include the selection and purchase of existing off-the-shelf software, basic installation, configuration (defined strictly as manipulating pre-coded parameters), employee training, data conversion, and routine maintenance or debugging that corrects errors but does not give rise to new upgrades or enhancements.

Explanatory Memoranda: IRS Notice 2023-63 and Procedural Guidance

On September 8, 2023, the Department of the Treasury and the Internal Revenue Service released an advance version of Notice 2023-63. This extensive document provides highly anticipated interim guidance on the application of the mandatory capitalization and amortization rules, describing anticipated proposed rules and interim reliance guidance for the TCJA’s Section 174 framework, subsequently clarified and modified by Notice 2024-12.

Cost Allocation Methodologies and Midpoint Conventions

Because modern corporate operations deeply intertwine R&D with general manufacturing and administration, the Notice requires taxpayers to allocate overhead and indirect costs to SRE activities based on a rigorous methodology. This methodology must establish a direct “cause-and-effect relationship” or another reasonable relationship that logically relates the costs incurred to the benefits provided by the SRE activities. While taxpayers are permitted to use different allocation methods for different types of costs—for instance, utilizing labor hours to allocate personnel overhead while using relative square footage to allocate facility rent and depreciation—the chosen methodology must be applied consistently across the enterprise for that specific cost type.

To operationalize the statutory requirement that amortization begins at the “midpoint” of the taxable year, Section 3 of the Notice establishes strict mechanical rules. For a standard 12-month taxable year, the midpoint is unequivocally defined as the first day of the seventh month. The Notice strictly prohibits the acceleration of amortization due to the occurrence of short taxable years, mandating that the 60-month or 180-month recovery periods remain absolute. For taxpayers experiencing a short tax year, the midpoint month is calculated mathematically. If the short tax year contains an even number of months, the midpoint month is determined by dividing the number of months by two and adding one (e.g., for a 6-month short year beginning January 1, the midpoint is April 1).

Contract Research: Assessing Financial Risk and Rights to Exploit

Historically, Section 174 lacked explicit statutory rules regarding research performed under contract, creating immense ambiguity for taxpayers offshoring development to foreign subsidiaries or utilizing third-party engineering and testing firms. Notice 2023-63, as modified by Notice 2024-12, addresses this issue through a two-pronged test applied to the “research provider” (the entity performing the work on behalf of a principal). Under the TCJA-era rules, a research provider must treat its relevant incurred costs as SRE expenditures if it meets either of the following conditions:

  • Financial Risk: The research provider contractually bears the risk of financial loss if the research fails to produce the desired product. This typically manifests in fixed-price contracts where payment is entirely contingent upon the successful delivery of a functional prototype or software module.
  • Rights to Exploit: The research provider retains the legal right to use the resulting SRE product in its own trade or business, or to independently exploit the product through sale, lease, or license to third parties. Notice 2024-12 clarifies that “excluded SRE product rights” include separately bargained-for rights or rights acquired for the limited purpose of performing research under a contract with the research recipient. Those rights alone do not trigger SRE treatment for a provider that bears no financial risk.

If the research provider bears no financial risk (e.g., operating under a standard time-and-materials contract) and retains no independent rights to exploit the intellectual property, its costs are not SRE expenditures under those provider rules and may be deductible under Section 162, subject to other applicable provisions. Conversely, the “research recipient” (the principal funding the research and retaining the IP) must separately evaluate the payments under the rules for research performed on its behalf; qualifying payments are subject to capitalization under the TCJA framework and to the applicable domestic or foreign treatment thereafter.

Interplay with Long-Term Contracts (Section 460) and Cost Sharing (Section 482)

The Notice addresses the interplay between Section 174 capitalization and the Percentage of Completion Method (PCM) governing long-term contracts under Section 460. Using the entire amount of incurred SRE costs to measure completion while deducting only amortization could create a mismatch between revenue recognition and cost recovery. The notice describes anticipated rules under which allocable SRE amortization, rather than the full capitalized expenditure, enters the completion calculation as deducted. This is interim guidance subject to its applicability and reliance conditions, not a universal rule for every research cost or long-term contract.

Regarding multinational intellectual property structures, the Notice addresses Cost Sharing Arrangements (CSAs) under Section 482. Notice 2023-63 proposes that Cost Sharing Transaction (CST) payments made between controlled participants would reduce the recipient’s capitalizable and deductible intangible development costs under the notice’s allocation rules. This is intended to align in the capitalization burden proportional to the reasonably anticipated benefits derived from the developed intangibles.

The “Dry Hole” Rule: Section 174(d) Dispositions and Abandonments

Historically, the tax code provided a safety valve for the inherent risk of innovation. If a research project failed (colloquially known as a “dry hole”) or the resulting prototype was abandoned, a taxpayer could potentially claim an abandonment loss under Section 165 for qualifying unrecovered capitalized costs, subject to the applicable requirements.

The TCJA restricted this recovery through the introduction of Section 174(d). Section 7 of Notice 2023-63 rigorously enforces this new statutory reality: if property with respect to which SRE expenditures were paid or incurred is disposed of, retired, or abandoned during the amortization period, no immediate deduction is allowed solely because of that event. Instead, the taxpayer must continue to amortize the SRE expenditures ratably over the remainder of the original 5-year or 15-year period.

This dynamic establishes a fundamental separation between the physical SRE property (the prototype or software) and the tax attribute (the SRE expenditure amortization base). This separation creates highly complex scenarios. For example, a corporation may invest heavily in a software module, determine it is commercially unviable in Year 1, and completely abandon the code. Despite the asset ceasing to exist, the corporation must continue amortizing its development costs on its tax returns for the remainder of the recovery period, which generally extends into Year 6 under the midpoint convention. This generation of a long-term deferred tax asset (DTA) that is disconnected from physical reality requires rigorous ASC 740 tax provision analysis, as auditors must evaluate whether a valuation allowance is required against the DTA based on available evidence about whether the tax benefit is more likely than not to be realized. For domestic TCJA-era balances, the subsequent transition elections can change the recovery schedule.

The 2025 OBBBA tightened the foreign-research disposition rule for property disposed of, retired, or abandoned after May 12, 2025: the relevant expenditures cannot produce a disposition deduction or reduce the amount realized, while amortization continues. Thus, the separation of the research expenditure amortization from the underlying property remains relevant.

Procedural Guidance and Accouability and the subsequent tax credit passed through to the partners or shareholders.

State R&D Credit Distinctions: The Gross Receipts Variance

California’s nonconformity extends beyond the deduction mechanics and into the calculation of its state-level Research and Development Tax Credit. While California R&TC heavily references federal IRC Section 41, it utilizes a distinct, geographically bound definition of “gross receipts” for calculating the base amount of the credit.

For California purposes, gross receipts only include sales of real, tangible, or intangible property held for sale to customers in the ordinary course of business that are delivered or shipped to a purchaser located within California. The state explicitly excludes service-related receipts, rents, or interest from this calculation. This narrower gross receipts definition can affect the regular-credit base amount and may increase the credit, subject to minimum-base and other limitations for technology and software companies that incur heavy R&D costs in California but primarily generate service or SaaS revenue from out-of-state customers. Other states, such as Connecticut, utilize entirely different thresholds, while New York and Pennsylvania have their own unique structural interactions with Section 174 that require localized analysis.

Texas Comptroller Interpretations

State executive branch interpretation extends beyond just California. In Texas, the Comptroller issued specific guidance regarding the interplay of Section 174 and the Texas Franchise Tax R&D credit. The guidance addressed whether an expense allowed under Section 174 for depreciable property could also qualify as a supply expense under Section 41. The Texas Comptroller explicitly rejected this argument, issuing a memo clarifying that qualification as an IRC Section 174 expense is a necessary, but not sufficient, condition under that framework for an expense to be a Qualified Research Expense (QRE). If the property is depreciable under Section 167, it remains excluded from the definition of supplies under Section 41(b)(2)(C), regardless of its Section 174 treatment. Current claims must also follow the Texas credit provisions applicable to the claim year.

Judicial Interpretation and Landmark Case Law

Federal courts and the U.S. Tax Court have fundamentally shaped the interpretation of what constitutes a valid Section 174 expenditure, the nature of depreciable property in the context of research, and the rigid documentation requirements necessary to substantiate the “process of experimentation.” These rulings provide the judicial guardrails that guide both IRS enforcement and taxpayer compliance.

TG Missouri Corp. v. Commissioner (133 T.C. 278)

In TG Missouri Corp. (2009), the Tax Court evaluated the complex intersection of Section 174 (R&E expenses), Section 41 (supplies), and Section 167 (depreciation). TG Missouri, an injection-molded automotive parts manufacturer, hired third-party toolmakers to construct production molds based on the taxpayer’s internal designs. Crucially, the taxpayer bore the economic risk that the molds would fail to meet specifications.

The IRS challenged the inclusion of these costs, arguing that because the molds were tangible assets, they were “property of a character subject to the allowance for depreciation” under Section 174(c). Under the IRS’s theory, this barred them from being treated as R&E expenditures, and consequently, rendered them ineligible as QRE supplies under Section 41.

The Tax Court ruled in favor of the taxpayer, establishing a critical precedent. The Court held that the phrase “property of a character subject to the allowance for depreciation” must be interpreted contextually; it means property that is depreciable in the hands of the specific taxpayer claiming the expense. Because TG Missouri ultimately sold the molds to its customers (with title passing upon completion and acceptance), the molds were classified as inventory/cost of goods sold, not as depreciable capital assets in TG Missouri’s hands. Consequently, the costs were not barred by Section 174(c) and were validly claimed as research supply expenses. The holding concerns molds that were not depreciable in the taxpayer’s hands and does not establish that all prototypes or tooling qualify.

Little Sandy Coal Co. v. Commissioner (62 F.4th 287)

While TG Missouri expanded taxpayer protections, the 7th Circuit’s affirmation of the Tax Court in Little Sandy Coal Co. (2023) underscored the importance of evidence regarding documentation and the rigid application of the Section 41(d)(1)(C) “process of experimentation” test.

The taxpayer, a shipbuilding enterprise, claimed significant R&D credits for the development of a novel “first-in-class” vessel and a dry dock. The IRS disallowed the credits entirely, arguing the taxpayer failed the “substantially all” (80%) process of experimentation test.

The 7th Circuit explained that direct support and supervision activities may enter the numerator of the 80% test when they actually constitute elements of experimentation; those labels alone do not establish qualification. The taxpayer failed to provide a principled allocation of experimental activities. The court also found that the taxpayer had not developed a supported claim under the shrink-back rule, rather than holding that every vessel must automatically be divided into subcomponents.

The taxpayer’s generalized descriptions and arbitrary estimates did not establish the required proportion of experimental activities. Little Sandy Coal illustrates that meeting the Section 174 expenditure test alone does not establish eligibility for the credit. Taxpayers need reliable evidence for the activities and costs claimed, including at the subcomponent level when the shrink-back rule is used; the decision does not mandate one universal timekeeping system.

Fairchild Industries v. United States (71 F.3d 868)

In evaluating contract research, Fairchild Industries (decided in 1995 and modified in 1996) remains an important appellate ruling on the funded-research exclusion now reflected in Section 41(d)(4)(H). The Federal Circuit focused on whether the taxpayer bore the risk of unsuccessful research and whether payment depended on meeting the contract’s requirements. Its funded-research analysis does not establish all the separate conditions for Section 174 treatment. Notice 2023-63 Section 6 separately addresses a research provider’s financial risk and product rights. Phoenix Design Group (2024) also illustrates the need to substantiate qualified research and experimentation; it should not be characterized as a ruling that merely penalized surrendering IP rights.

Practical Example: Federal Amortization vs. California Expensing

To illuminate the stark divergence between the federal TCJA framework and California’s nonconformity, consider a hypothetical software engineering firm, TechNova Inc., operating exclusively in Silicon Valley, California. Assume a calendar tax year, no other income adjustments or credit-related deduction reductions, and no retroactive OBBBA election affecting 2024.

During the 2024 tax year, TechNova incurs exactly $1,200,000 in domestic software development costs. These costs are assumed to qualify as SREs under federal law and as R&E expenditures under California law. TechNova generated $2,000,000 in gross profit before accounting for these R&D expenses.

Federal Tax Posture (The TCJA Capitalization Framework): Under the TCJA rules applicable to this example, TechNova is prohibited from deducting the $1,200,000 as an operating expense. It must capitalize the amount and amortize it over 5 years (60 months). Using the mandatory half-year (midpoint) convention established by Notice 2023-63, TechNova can only amortize 10% of the cost (representing 6 months of a 60-month period) in Year 1.

TechNova Inc. Federal Tax Calculation (2024)
Federal Tax Calculation Amount
Gross Profit $2,000,000
Federal R&E Amortization Deduction (Year 1) -$120,000 ($1.2M x 10%)
Federal Taxable Income $1,880,000
Unamortized Basis Carried to Year 2 $1,080,000

California Tax Posture (2024 State Treatment): The California FTB does not conform to the TCJA capitalization mandate. TechNova is permitted to immediately expense the entire $1,200,000 cost.

TechNova Inc. California Tax Calculation (2024)
California Tax Calculation Amount
Federal Taxable Income (Starting Point) $1,880,000
California Federal Add-back (Reversing the Amortization) +$120,000
California R&E Deduction (Immediate Expensing) -$1,200,000
California Taxable Income $800,000
Net California Adjustment on FTB Forms -$1,080,000

In this hypothetical taxable year, federal taxable income is more than double California taxable income. The $1,080,000 unamortized balance is a deductible temporary difference, not itself the amount of a deferred tax asset (DTA). For federal ASC 740 reporting, the associated DTA is measured using the applicable enacted tax rate and evaluated for a valuation allowance. If TechNova abandons the software in 2025, abandonment alone does not accelerate the legacy domestic deductions. However, the OBBBA transition election may allow the remaining balance to be recovered in 2025 or over 2025 and 2026, rather than continuing the original schedule through 2029.

Swanson Reed’s Technical Approach

Navigating the interplay between Section 174 capitalization, Section 174A domestic deductions, Section 41 credits, and state nonconformity requires tax and technical expertise. Swanson Reed describes its practice as combining technical specialists with tax professionals and audit support. Whether that approach is suitable for a particular taxpayer depends on the engagement team and the supporting evidence. As Little Sandy Coal illustrates, high-level allocations without adequate substantiation can put claims at risk, regardless of the type of advisory firm preparing them.

Swanson Reed states that it uses engineers, scientists, and accounting professionals, together with tax technology, in its R&D credit services. Such an approach may help connect a taxpayer’s engineering activities to relevant tax requirements, including distinctions between routine maintenance and software upgrades or enhancements. Taxpayers should verify the assigned team’s qualifications and the scope of any tools used for unamortized research-cost tracking, Section 280C(c) elections, and federal-to-state adjustments. These capabilities and successful audit outcomes should not be assumed or guaranteed.

Final Thoughts

26 U.S. Code Section 174, once a relatively simple statutory framework designed to encourage immediate expensing, has evolved into a highly complex, multi-layered regulatory and accounting regime. The TCJA’s mandate to capitalize and amortize domestic and foreign research—and the subsequent partial reversals introduced by the 2025 OBBBA—have fundamentally altered corporate financial planning. This new era demands meticulous cost segregation, forcing companies to strictly delineate between SREs and ordinary operating expenses.

IRS Notice 2023-63, as clarified and modified by Notice 2024-12, provides interim guidance on midpoint conventions, cost allocation, contract research, and continued amortization after dispositions. Its TCJA-era rules must be read alongside Section 174A and the OBBBA transition provisions. Cases such as Little Sandy Coal and TG Missouri show why both the underlying activities and the specific statutory exclusions matter. California’s retained expensing rules can produce deduction timing differences, particularly for legacy balances and foreign research, requiring separate federal and state tracking. Effective planning therefore considers the Section 41 credit, research-cost deductions and capitalization, and state compliance together.

Frequently Asked Questions

How did the TCJA change the tax treatment of research expenditures under Section 174?

For tax years beginning after December 31, 2021, the TCJA required taxpayers to capitalize specified research or experimental expenditures and amortize them over five years for domestic research and 15 years for foreign research, beginning at the midpoint of the taxable year.

What does Section 174A change for tax years beginning after December 31, 2024?

Section 174A, enacted by the 2025 One Big Beautiful Bill Act, generally permits the immediate deduction of domestic research and experimental expenditures, including domestic software development costs, while foreign research expenditures remain subject to 15-year amortization.

Does California follow the federal Section 174 capitalization rules?

No. California does not conform to the TCJA capitalization mandate or the Section 174A amendments, so domestic and foreign research and experimental expenditures generally remain eligible for immediate deduction for California purposes, which requires separate federal and state tracking.

About the Author

Jess Doocey, R&D Tax Credit Preparation and R&D Tax Credit Audit Advisory Specialist

Jess Doocey is an R&D Tax Credit Preparation and R&D Tax Credit Audit Advisory Specialist at Swanson Reed.

Areas of expertise: Federal R&D Tax Audit and appeals, Federal R&D Tax Credits

About the Author

Adam Rogers, Principal & Partner

Adam Rogers is a Principal & Partner at Swanson Reed – Specialist R&D Tax Advisors.

Areas of expertise: R&D tax credit audit and defense, Mechanical Engineering

Who We Are: Swanson Reed is one of the largest Specialist R&D Tax Credit advisory firm in the United States. With offices nationwide, we are one of the only firms globally to exclusively provide R&D Tax Credit consulting services to our clients. We have been providing R&D Tax Credit claim preparation and audit compliance solutions since 1984. Swanson Reed hosts daily free webinars and provides free IRS CE and CPE credits for CPAs.

Are you eligible?

R&D Tax Credit Eligibility AI Tool

Why choose us?

R&D tax credit

Pass an Audit?

R&D tax credit

What is the R&D Tax Credit? The Research & Experimentation Tax Credit (or R&D Tax Credit), is a general business tax credit under Internal Revenue Code section 41 for companies that incur research and development (R&D) costs in the United States. The credits are a tax incentive for performing qualified research in the United States, resulting in a credit to a tax return. For the first three years of R&D claims, 6% of the total qualified research expenses (QRE) form the gross credit. In the 4th year of claims and beyond, a base amount is calculated, and an adjusted expense line is multiplied times 14%. Click here to learn more.

Never miss a deadline again

R&D tax credit

Stay up to date on IRS processes

Discover R&D in your industry

R&D Tax Credit Preparation Services Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed provides state and federal R&D tax credit preparation and audit services to all 50 states. If you have any questions or need further assistance, please call or email our CEO, Damian Smyth on (800) 986-4725. Feel free to book a quick teleconference with one of our national R&D tax credit specialists at a time that is convenient for you.

R&D Tax Credit Audit Advisory Services creditARMOR is a sophisticated R&D tax credit AI agent driven risk mock audit platform. It mitigates audit exposure by covering defense expenses, including CPA, tax attorney, and specialist consultant fees—delivering robust, compliant support for R&D credit claims. Click here for more information about R&D tax credit management and implementation.

Our Fees Swanson Reed offers R&D tax credit preparation and audit services at our hourly rates of between $195 – $395 per hour. We do not offer contingency fees but we can offer fixed fees in special circumstances. Learn more at https://www.swansonreed.com/services/our-fees/

R&D Tax Credit Training for CPAs

R&D tax credit

Upcoming Webinars

R&D Tax Credit Training for CFPs

bigstock Image of two young businessmen 521093561 300x200

Upcoming Webinars

R&D Tax Credit Training for SMBs

water tech

Upcoming Webinars
Contact Us

Send us a message and we will be in touch shortly!

Start typing and press Enter to search